[3] [3] MULINARI-BRENNER F. Psychosomatic aspects of alopecia areata［J］. Clinics in Dermatology, 2018, 36(6): 709-713.

[4] [4] MANSTEIN D, HERRON G S, SINK R K, et al. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury ［J］. Lasers in Surgery and Medicine, 2004, 34(5): 426-438.

[9] [9] BERTIN A C J , VILARINHO A , JUNQUEIRA A L A. Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss［J］. Journal of Cosmetic and Laser Therapy, 2018, 20(7/8): 391-394.

[10] [10] WU Y E, WANG S H, WU P S, et al. Enhancing hair follicle regeneration by nonablative fractional laser: assessment of irradiation parameters and tissue response［J］. Lasers in Surgery and Medicine, 2015, 47(4): 331-341.

[12] [12] TANAKOL A, OBA M C, UZUNCAKMAK T K, et al. Treatment of alopecia areata with 2 940 nm fractional erbium: yttrium-aluminum-garnet laser［J］. Dermatologic Therapy, 2020, 33(6): e13978.

[15] [15] CHO S B. Therapeutic efficacy of 1 927 nm fractionated thulium laser energy and polydeoxyribonucleotide on pattern hair loss［J］. Medical Lasers, 2016, 5(1): 22-28.

[17] [17] TANG G, XIONG J, FAN Q, et al. Plum-blossom needle plus Chinese herbal medicine for alopecia areata: a protocol for systematic review and meta analysis［J］. Medicine, 2020, 99(41): e22515.

[22] [22] DAI T, SONG N, LI B. Add-on effect of plum-blossom needling in alopecia areata: a qualitative evidence synthesis［J］. Annals of Palliative Medicine, 2021, 10(3): 3000-3008.

[23] [23] ZHANG Q L, FU X H, YING X F, et al. Treatment of alopecia areata with plum-blossom needles plus moxibustion: a report of 53 cases［J］. Journal of Acupuncture and Tuina Science, 2004, 2(1): 40-41.

[24] [24] LIU Z D, WANG Q L, BEI F, et al. Effect of plum-blossom needle tapping with different stimulation intensities on hair regrowth in hair removal mice［J］. Journal of Acupuncture and Tuina Science, 2017, 15(3): 184-190.

[26] [26] MING L, MARUBAYASHI A, NAKAYA Y, et al. Minoxidil-Induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil［J］. Journal of Investigative Dermatology, 2001, 117(6): 1594.

[27] [27] WAMBIER C G, CRAIGLOW B G, KING B A. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata［J］. Journal of the American Academy of Dermatology, 2021, 85(3): 743-745.

[28] [28] RIZG W Y, HOSNY K M, ELGEBALY S S, et al. Preparation and optimization of garlic oil/apple cider vinegar nanoemulsion loaded with minoxidil to treat alopecia［J］. Pharmaceutics, 2021, 13(12): 2150.

[29] [29] RANDOLPH M, TOSTI A. Oral minoxidil treatment for hair loss: a review of efficacy and safety［J］. Journal American Academy of Dermatology, 2021, 84(3): 737-746.

[30] [30] XING L, DAI Z, JABBARI A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nature Medicine, 2014, 20(9): 1043-1049.

[31] [31] PARK H, YU D A, KWON O, et al. Janus kinase inhibitors: an innovative treatment for alopecia areata［J］. Journal of Dermatology, 2019, 46(8): 724-730.

[32] [32] HAREL S, HIGGINS A C, CERISE E J, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth［J］. Science Advances, 2015, 1(9): e1500973.

[33] [33] DILLON K L. A comprehensive literature review of JAK inhibitors in treatment of alopecia areata［J］. Clinical Cosmetic and Investigational Dermatology, 2021, 14: 691-714.

[34] [34] LIU Y L, GRAIGLOW G B, DAI F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients［J］. Journal of American Academy of Dermatology, 2017, 76(1): 22-28.

[35] [35] KO M J, CRAIGLOW G B, LI S, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata［J］. JCI Insight, 2016, 1(15): e89776.

[36] [36] KING B, PEEVA E, GUTTMAN-YASSKY E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results［J］. Journal of American Academy Dermatology, 2021, 85(2): 379-387.

[38] [38] MESSENGER A G, MCKILLOP J, FARRANT P, et al. British association of dermatologists’ guidelines for the management of alopecia areata 2012［J］. British Journal of Dermatology, 2012, 166(5): 916-926.